Part of VetDC’s Clinical Advisory Board Guest Blog series. This post comes from Brenda Phillips, DVM, ACVIM (Oncology) at the Veterinary Specialty Hospital of San Diego.
2015 marks the 25th anniversary of the Veterinary Specialty Hospital of San Diego (VSH). Renowned for innovative medical care, we are proud to have led many pioneering advances in veterinary oncology.
These range from participating in novel therapeutic clinical trials, being the first hospital in the region to have a linear accelerator to treat cancers with radiation therapy, performing minimally invasive cardiac procedures for dogs with heart tumors, and performing successful bone marrow transplants for canine lymphoma patients.
I am very proud to be part of the medical team at VSH. We believe that our companion animal patients deserve the care and oversight of as many skilled and compassionate medical caretakers as necessary to achieve an optimal healing environment. We are also passionate about giving back to the veterinary community, providing dynamic and robust educational programs to doctors, technicians and front office staff at no cost. We train the next generation of veterinarians through our internship and residency programs, fund patient care via our financial assistance foundation, and participate in numerous charitable events throughout the San Diego community. We are extremely optimistic about the future of veterinary medicine and are passionate about bringing better veterinary medical care to our local and global communities.
The oncology service at VSH is particularly excited about its role in development of the next phase of veterinary cancer care. In spite of decades of development of various chemotherapy protocols for canine lymphoma patients (originally derived from human generic drugs) patient outcomes have not significantly improved. We need new approaches, such as immunotherapy, targeted therapy based on genetics of a patient’s cancer, and novel anti-cancer therapeutics specifically targeted for use in pets. At VSH, we continually collaborate with innovative companies dedicated to improving animal health, and one such company, VetDC, is currently supporting several of our current clinical trials. These trials are designed to optimize treatment protocols by utilizing Tanovea™-CA1, a novel anti-cancer agent for the treatment of canine lymphoma. We are thrilled to be able to offer such a treatment for our patients and look forward to the day when such products are widely available for all canine lymphoma patients.
To learn more about Brenda Phillips and her team’s work at the Veterinary Specialty Hospital of San Diego, please visit www.vshsd.com.